Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving LENZ Therapeutics, Inc. following a significant drop in its stock price due to adverse event reports related to its product [1][3]. Group 1: Investigation Details - Pomerantz LLP is representing investors of LENZ Therapeutics, Inc. and is looking into whether the company and its officers or directors have engaged in fraudulent activities [1]. - The investigation was prompted by a report of a retinal tear associated with LENZ's VIZZ eye drop, which was recorded in the FDA's adverse event reporting systems [3]. Group 2: Stock Price Impact - Following the adverse event report on December 12, 2025, LENZ's stock price decreased by $6.36 per share, representing a decline of 25.96%, closing at $18.14 per share on that date [3]. Group 3: Firm Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering significant damages for victims of securities fraud and corporate misconduct [4].

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Ramaco Resources, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Investigation Details - The investigation is prompted by allegations from Wolfpack Research that Ramaco's Brook Mine project is a "hoax" and that the company manipulated data to misrepresent its profitability to investors [3]. - Following the allegations, Ramaco's stock price experienced a significant decline, falling by $3.81 per share, or 9.57%, closing at $36.01 per share on October 23, 2025 [3]. Group 2: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of over 85 years in fighting for victims of securities fraud and corporate misconduct [3].

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Above Foods Ingredients Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Company Developments - On December 2, 2025, Above Food disclosed that its auditor had resigned in July at the company's request [3]. - Following the auditor's resignation announcement, Above Food's stock price fell by $0.23 per share, or 7.67%, closing at $1.69 per share on December 19, 2025 [3]. Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [4].

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Company Performance - On December 16, 2025, Nektar announced topline results from the Phase 2b REZOLVE-AA trial of its investigational drug rezpegaldesleukin, which failed to reach statistical significance due to the inclusion of four ineligible patients [3]. - Following the announcement of the trial results, Nektar's stock price dropped by $4.14 per share, or 7.77%, closing at $49.16 per share on the same day [4]. Group 2: Legal Investigation - Pomerantz LLP, a firm known for its work in corporate and securities class litigation, is leading the investigation into Nektar's business practices and potential fraud [5].

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Charming Medical Limited regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Investigation and Legal Actions - The U.S. Securities and Exchange Commission (SEC) issued an order to halt trading of Charming Medical securities due to potential manipulation through social media recommendations aimed at artificially inflating the price and trading volume of the company's securities [3]. - Trading in Charming Medical's securities was suspended starting on November 12, 2025, following the SEC's order [3]. Group 2: Pomerantz LLP Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of over 85 years in fighting for the rights of victims of securities fraud and corporate misconduct [4]. - The firm has successfully recovered numerous multimillion-dollar damages awards on behalf of class members [4].

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Company Performance - On December 17, 2025, Insmed announced that the Phase 2b BiRCh study of brensocatib in patients with chronic rhinosinusitis without nasal polyps did not meet its primary or secondary efficacy endpoints in both the 10 mg and 40 mg treatment arms [3]. - Following the announcement of the trial results, Insmed's stock price dropped by $31.91 per share, representing a decline of 16.08%, closing at $166.55 per share on December 18, 2025 [3]. Group 2: Legal Investigation - Pomerantz LLP, a firm recognized for its expertise in corporate, securities, and antitrust class litigation, is leading the investigation into Insmed's potential misconduct [4]. - The firm has a history of recovering significant damages for victims of securities fraud and corporate misconduct, indicating a strong focus on protecting investor rights [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Cogent Communications Holdings, Inc. and its officers or directors [1] Financial Performance - On November 6, 2025, Cogent reported a year-over-year service revenue decline of nearly 6% for the third quarter of 2025 [3] - The company announced a drastic dividend cut of 98%, reducing it from $1.015 per share in the previous quarter to $0.02 per share [3] - Following the announcement, Cogent's stock price dropped by $13.35 per share, or 34.86%, closing at $24.95 per share on the same day [3]

Core Viewpoint - Jefferies Financial Group Inc. is facing scrutiny due to its financial exposure to First Brands Group, which has filed for bankruptcy, leading to investigations that impact investor confidence [1][4]. Financial Performance - Jefferies' stock is currently priced at $63.16, reflecting a slight increase of 2.15% or $1.33, with recent fluctuations between $62.17 and $63.90 [3][6]. - The stock has experienced significant volatility over the past year, with a high of $82.68 and a low of $39.28, indicating market uncertainty regarding the company's future [3][6]. Market Position - The market capitalization of Jefferies is approximately $13.03 billion, with a trading volume of 212,986 shares on the NYSE [4]. Analyst Insights - Oppenheimer has set a new price target of $97 for Jefferies, suggesting a potential increase of approximately 52.88% from its current trading price of $63.45 [2][6]. - Jefferies has a financial exposure of $715 million in receivables from First Brands Group, which constitutes about 25% of Point Bonita Capital's portfolio [2][6]. Investigations and Legal Concerns - Ongoing investigations by law firms and the SEC are raising concerns about potential violations of federal securities laws, which are affecting investor sentiment [4][5].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Alaska Air Group and its officers or directors [1] Group 1: Company Investigation - Pomerantz LLP is representing investors of Alaska Air Group, indicating possible legal issues related to securities fraud [1] - The investigation follows a significant IT outage that led to a systemwide ground stop for Alaska and Horizon Air flights, resulting in operational disruptions [2] Group 2: Stock Market Reaction - Following the announcement of the IT outage, Alaska Air's stock price dropped by $2.86, or 6.13%, closing at $43.77 per share on October 24, 2025 [2]

NEW YORK, Dec. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  CoreWeave, Inc. ("CoreWeave" or the "Company") (NASDAQ: CRWV). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether CoreWeave and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On November 10, 20 ...